The ICD-10 code C64 signifies a malignant neoplasm (cancer) originating in the kidney, specifically excluding the renal pelvis. This encompasses various histological subtypes of kidney cancer, such as renal cell carcinoma (the most common type), clear cell carcinoma, papillary renal cell carcinoma, and chromophobe renal cell carcinoma. Understanding the distinction between C64 and codes related to the renal pelvis (C65) is crucial for accurate diagnosis, treatment, and epidemiological tracking. The National Cancer Institute provides comprehensive information regarding kidney cancer statistics and research. Explore how S10.AI can assist with accurate ICD-10 coding.
Clinical presentation of C64 can vary, with some patients remaining asymptomatic in early stages. Common symptoms include hematuria (blood in the urine), flank pain, palpable abdominal mass, weight loss, fatigue, and fever. Less common symptoms may include hypertension, hypercalcemia, and varicocele. Early detection is often incidental during imaging studies performed for other reasons. For a detailed overview of kidney cancer symptoms and diagnosis, refer to the Mayo Clinic's resources. Consider implementing S10.AI to enhance patient data analysis and symptom tracking.
Staging of C64 renal cancer generally follows the TNM system (Tumor, Node, Metastasis), which considers tumor size, lymph node involvement, and distant metastasis. Prognostic factors influencing survival rates include tumor stage, grade (cellular differentiation), patient performance status, and the presence of specific molecular markers. The American Cancer Society offers in-depth information on kidney cancer staging and prognosis. Learn more about how S10.AI can integrate with existing EHR systems to facilitate staging and prognosis documentation.
Treatment options for C64 depend on the stage and grade of the cancer, patient's overall health, and preferences. Options include surgical resection (partial or radical nephrectomy), targeted therapy (inhibiting specific molecular pathways involved in cancer growth), immunotherapy (activating the immune system to fight cancer), and radiation therapy. For localized disease, surgery is often the primary treatment. For advanced disease, systemic therapies are typically used. Explore how S10.AI can help clinicians stay up-to-date with the latest treatment guidelines and research. The National Comprehensive Cancer Network (NCCN) provides evidence-based guidelines for kidney cancer management.
AI-powered platforms like S10.AI can assist in various aspects of C64 management, including automated medical coding, efficient documentation, patient data analysis for risk stratification, identification of clinical trial eligibility, and providing clinicians with real-time access to the latest research and treatment guidelines. By streamlining workflows and providing data-driven insights, S10.AI can enhance the quality of care for patients with kidney cancer. Learn more about S10.AI's capabilities and its potential to improve oncology care.
Following treatment for C64, patients require ongoing surveillance to monitor for recurrence or development of new primary tumors. Follow-up generally includes regular imaging studies (CT scans, MRI), blood tests, and physical exams. The frequency and duration of follow-up depend on the individual patient's risk factors and treatment received. Consider implementing S10.AI to automate follow-up scheduling and reminders, ensuring comprehensive patient care. The American Society of Clinical Oncology (ASCO) provides guidelines for cancer survivorship care.
Several conditions can mimic the symptoms of C64, including renal cysts, renal abscesses, renal infarcts, and other benign renal tumors. Accurate diagnosis relies on imaging studies (CT, MRI, ultrasound), biopsy, and pathological evaluation. Understanding the differential diagnosis of C64 is crucial for avoiding unnecessary interventions and ensuring appropriate management. Explore how S10.AI can assist in differential diagnosis by providing clinicians with access to relevant medical literature and diagnostic tools.
Ongoing research is exploring new therapeutic targets and innovative treatment approaches for C64, including novel immunotherapies, combination therapies, and personalized medicine strategies based on molecular profiling. The National Institutes of Health (NIH) offers resources on current research efforts in kidney cancer. Learn more about how S10.AI can help clinicians stay informed about cutting-edge research and emerging treatment options.
Long-term survival rates for C64 vary depending on the stage at diagnosis. Generally, early-stage localized disease has a more favorable prognosis compared to advanced-stage disease with distant metastasis. The Surveillance, Epidemiology, and End Results (SEER) program provides data on cancer survival statistics. Explore how S10.AI can be used to analyze patient data and provide personalized prognostic information.
| Stage | 5-Year Relative Survival Rate (Approximate) |
|---|---|
| Localized | 93% |
| Regional | 70% |
| Distant | 13% |
Note: These are approximate figures and individual outcomes can vary based on several factors. Consult the SEER database for detailed statistics.
Genetic testing can identify specific genetic mutations associated with an increased risk of developing kidney cancer, particularly in individuals with a family history of the disease. Genetic information can also be used to guide treatment decisions and personalize therapeutic approaches. The National Human Genome Research Institute provides information on the role of genetics in cancer. Learn more about how S10.AI can integrate genetic data into patient records for comprehensive risk assessment and treatment planning.
Lifestyle modifications, such as maintaining a healthy weight, following a balanced diet, engaging in regular physical activity, and avoiding tobacco use, are recommended for patients with C64 to improve overall health and potentially reduce the risk of recurrence. The American Cancer Society offers guidelines on lifestyle choices and cancer prevention. Explore how S10.AI can assist in providing patients with personalized lifestyle recommendations and resources.
What are the key differentiating features in diagnosing a C64 malignant neoplasm of the kidney, excluding the renal pelvis, compared to renal pelvic tumors?
Distinguishing a C64 malignant neoplasm (renal parenchyma) from a renal pelvic tumor relies on imaging (CT/MRI) showing the origin and extent of the tumor. Renal parenchymal tumors typically arise from the cortex or medulla of the kidney, while renal pelvic tumors originate in the lining of the renal pelvis. Histopathology following biopsy or resection confirms the diagnosis and provides crucial information for staging and treatment planning, including specific cell types, as the renal parenchyma and pelvis have different common tumor types. Explore how AI-powered EHR integration can expedite diagnostic processes by automatically analyzing imaging data and surfacing relevant histological findings for efficient differential diagnosis.
How does the TNM staging for a C64 malignant neoplasm (kidney, excluding renal pelvis) influence treatment decisions and prognosis?
The TNM staging system (Tumor size/local extent, Node involvement, Metastasis) is critical for determining the appropriate treatment approach for C64 malignant neoplasms. A localized tumor (T1-T3) may be treated with partial or radical nephrectomy. Lymph node involvement (N1-N2) often requires more aggressive surgical resection and consideration of adjuvant therapies. Distant metastasis (M1) signifies advanced disease and usually involves systemic therapies like targeted therapy or immunotherapy, potentially with cytoreductive nephrectomy. Consider implementing an AI-driven EHR agent that can automatically stratify patients by TNM stage and facilitate streamlined access to stage-appropriate treatment guidelines and clinical trials, improving patient care.
What are the latest advancements in targeted therapies and immunotherapies for metastatic C64 malignant neoplasm (kidney, excluding renal pelvis), and how can AI EHR integration improve access to these treatments?
Metastatic C64 malignancies have seen significant advancements in treatment, especially with targeted therapies against VEGF, mTOR, and other pathways, as well as immunotherapies like checkpoint inhibitors. Choosing the optimal treatment strategy involves careful consideration of the patient's individual tumor characteristics, including molecular profiling results, as well as performance status and comorbidities. Learn more about how universal EHR integration with AI agents can streamline access to genomic testing and facilitate rapid matching of patients to appropriate targeted therapies and clinical trials, personalizing cancer care and ensuring access to the most current treatment options.
Hey, we're s10.ai. We're determined to make healthcare professionals more efficient. Take our Practice Efficiency Assessment to see how much time your practice could save. Our only question is, will it be your practice?
We help practices save hours every week with smart automation and medical reference tools.
+200 Specialists
Employees4 Countries
Operating across the US, UK, Canada and AustraliaWe work with leading healthcare organizations and global enterprises.